HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: R600008-MCP200v1 5/10/1819    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Azad, N. S. Articles by Kohn, E. C. Search for Related Content PubMed PubMed Citation Articles by Azad, N. S. Articles by Kohn, E. C. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 5:1819-1829, 2006.
© 2006 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Cancer

Proteomics in Clinical Trials and Practice

Present Uses and Future Promise^*

Nilofer S. Azad, Nabila Rasool, Christina M. Annunziata, Lori Minasian, Gordon Whiteley and Elise C. Kohn

From the Laboratory of Pathology, Molecular Signaling Section, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892

The study of clinical proteomics is a promising new field that has the potential to have many applications, including the identification of biomarkers and monitoring of disease, especially in the field of oncology. Expression proteomics evaluates the cellular production of proteins encoded by a particular gene and exploits the differential expression and post-translational modifications of proteins between healthy and diseased states. These biomarkers may be applied towards early diagnosis, prognosis, and prediction of response to therapy. Functional proteomics seeks to decipher protein-protein interactions and biochemical pathways involved in disease biology and targeted by newer molecular therapeutics. Advanced spectrometry technologies and new protein array formats have improved these analyses and are now being applied prospectively in clinical trials. Further advancement of proteomics technology could usher in an era of personalized molecular medicine, where diseases are diagnosed at earlier stages and where therapies are more effective because they are tailored to the protein expression of a patient’s malignancy.

To whom correspondence may be addressed.: Laboratory of Pathology, NCI, National Institutes of Health, 10 Center Dr. MSC 1500, Bethesda, MD 20892. Tel.: 301-402-2726; Fax: 301-480-5142; E-mail: kohne{at}mail.nih.gov

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				U. Kruse, M. Bantscheff, G. Drewes, and C. Hopf Chemical and Pathway Proteomics: Powerful Tools for Oncology Drug Discovery and Personalized Health Care Mol. Cell. Proteomics, October 1, 2008; 7(10): 1887 - 1901. [Abstract] [Full Text] [PDF]